OUR MISSION

The Amyloidosis Research Consortium is a nonprofit accelerating the development of and access to new and innovative treatments. We are driving the research that will have the greatest impact on length and quality of life for patients.
MESSAGE FROM OUR CEO

Dear Friends,

2020 will forever be etched in our memories as the year of the pandemic. It is a year that reshaped the world.

One can only marvel at the power of science and the pace of discovery that occurred, as 2020 was marked by the race for an effective vaccine for COVID-19, harnessing the power of researchers across the globe. The pandemic also framed for us all the challenges and opportunities that exist in medicine today. For many with pre-existing conditions like amyloidosis it was an extremely difficult time, there was an added level of anxiety, disruption to care, while, novel approaches, including, for many, virtual visits became the new normal.

At ARC, we were able to quickly adapt our initiatives this year in order to meet the changing needs of the community; we led the way in supporting and keeping the patients informed about how best to manage their amyloidosis during the pandemic.

Despite the disruptions of a global pandemic, we also successfully advanced and grew our research programs. Moving into the virtual arena, has increased the opportunities for global collaboration, which the logistics of face-to-face meetings did not allow. In the rare disease space, international collaboration is vitally important, and virtual tools have provided new ways to facilitate that. Nowhere was this more clearly demonstrated than through the work that is being done within the Amyloidosis Forum, which is creating a unique, rigorous and truly international approach to improving the pathways for drug development and review.

Despite the challenges we all faced, I could not be prouder of the ARC team, who rose to the occasion, supported patients and drove our portfolio of research initiatives forward. Thanks to all of you we have continued to grow our programs, to advance the mission of ARC and together with your support we can make a difference and change the lives of those affected by amyloidosis.

Isabelle Lousada

Because ARC was founded by a patient, we have a razor-sharp focus on the patient. It is the reason we relentlessly pursue our goal of improving treatments and the lives of amyloidosis patients.
A LOOK BACK

ARC has grown rapidly since its inception in 2015. Our approach has delivered high impact programs focused on patients’ needs and has positioned ARC as a leader in the field of rare disease research.

Research Landscape White Paper
ARC convened leading experts across academia, industry regulatory and other areas for a two-day workshop. Resulting in the identification and publication of the most pressing needs in research across the drug development continuum, to focus research initiatives.

Cardiac Awareness Campaign
Misdiagnosis and delays are common in amyloidosis. This campaign was aimed at physicians who had missed the diagnosis and featured an Olympic champion diagnosed with amyloidosis.

Patient Experience Study
First-of-its-kind study to define the amyloidosis patient journey from diagnosis through treatment, and impact on quality of life.

Research Roundtable
First meeting of researchers, FDA and industry to address challenges of drug development in amyloidosis.

Biomarker Publication
Landmark paper on the importance of the biomarker NT-proBNP in AL amyloidosis.

MAP
My Amyloidosis Pathfinder (MAP) was developed to enable patients to stay informed about research and clinical trials opportunities, and connect them with amyloidosis treatment centers.

Clinical Resources App
Developed an interactive app to support clinicians in diagnosing and treatment patients. It has been associated with an increase in the diagnosis of amyloidosis.

Patient Voice Publication
A unique publication that was developed to be shared with the FDA and contains a valuable benefit/risk framework for use in product review.

Guidelines for suspicion and diagnosis of ATTR amyloidosis
Led on the publication of guidelines to support earlier diagnosis across multiple medical disciplines.

International Cardiac Study
This international study was the first to evaluate patient’s experiences with cardiac amyloidosis, and identity challenges in practices that need to be addressed.

Onpattro approved for ATTR-PN
September 2018

Tegsedi approved for ATTR-PN
October 2018

Vyndaqel approved for ATTR-CM
June 2019

Darzalex Faspro approved for AL
January 2021

FDA Drug Development Meeting
Our Patient Focused Drug Development Meeting with FDA generated data and reports about patient experiences – this first-of-its-kind meeting was so successful that a pathway has been established for other rare diseases.

Biomarker Publication
Landmark paper on the importance of the biomarker NT-proBNP in AL amyloidosis.

Clinical Resources App
Developed an interactive app to support clinicians in diagnosing and treatment patients. It has been associated with an increase in the diagnosis of amyloidosis.

Patient Voice Publication
A unique publication that was developed to be shared with the FDA and contains a valuable benefit/risk framework for use in product review.

Guidelines for suspicion and diagnosis of ATTR amyloidosis
Led on the publication of guidelines to support earlier diagnosis across multiple medical disciplines.

International Cardiac Study
This international study was the first to evaluate patient’s experiences with cardiac amyloidosis, and identity challenges in practices that need to be addressed.

Onpattro approved for ATTR-PN
September 2018

Tegsedi approved for ATTR-PN
October 2018

Vyndaqel approved for ATTR-CM
June 2019

Darzalex Faspro approved for AL
January 2021

Amyloidosis Research Consortium

2015

2016

2017

2018

2019

2020

2015

2016

2017

2018

2019

2020

Onpattro approved for ATTR-PN
September 2018

Tegsedi approved for ATTR-PN
October 2018

Vyndaqel approved for ATTR-CM
June 2019

Darzalex Faspro approved for AL
January 2021

AAC
The Amyloidosis Appointment Companion (AAC), a digital tool, was developed and provides a framework for patients to share information and concerns with their physician. The tool was integrated into virtual visits during COVID.

PRO Development
Initiated the development of a tool to capture all the aspects of ATTR amyloidosis that matter to patients, to be used in both clinical trials and clinical care.

Masterclass
In 2020, we established these physician masterclasses, which are held regionally, and focus on building expertise in centers in areas that are underserved.

Amyloidosis Forum
Formed a Public Private Partnership with FDA to advance and accelerate the science of drug development through multi-stakeholder collaboration.
Before ARC, there were no FDA approved treatments for amyloidosis. We now have four approved therapies for systemic amyloidosis and a portfolio of clinical trials to evaluate promising new agents.

<table>
<thead>
<tr>
<th>DRUG DEVELOPMENT PIPELINE</th>
<th>Pre-Clinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Commercial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alnylam - Onpattro hATTR-PN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Akcea - Tegsedi hATTR-PN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pfizer - Vyndagel/Vyndamax ATTR-CM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Janssen – Darzalex AL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eidos - AG10 ATTR-CM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alnylam - Vitrusiran ATTR-PN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alnylam - Patisiran ATTR-CM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alnylam - Vitrusiran ATTR-CM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AKCEA-TTR-LRxATTR-PN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caelum - Cael-101 (T11F4) AL</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AKCEA-TTR-LRx ATTR-CM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Prothena - PRX004 ATTR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intellia – CRISPR ATTR-PN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
WHAT WE DO

We enable pioneering research to better understand the factors responsible for the onset and progression of amyloidosis.

We accelerate the discovery and development of new and effective treatments and support their approval, reimbursement, adoption and diffusion into health systems across the world.

We raise awareness and provide education for physicians about the signs, symptoms and care of amyloidosis to raise the level of suspicion, improve the speed of diagnosis, and standards of care.

We provide information and support for patients and their families to help them cope with everything an amyloidosis diagnosis brings and to empower them to make informed decisions about treatment and care.

URGENCY
Patients needs drive us with a focus and determination to speed discovery and improve lives.

INNOVATION
We believe in finding transformative solutions to increase knowledge and advance research.

COLLABORATION
We build unique partnerships between patients, the scientific community regulators and other stakeholders to break down the barriers that slow research.
2020 was a year of many achievements for the Amyloidosis Research Consortium. These highlights showcase some of our many areas of impact.
ACCELERATING DRUG DEVELOPMENT

The Amyloidosis Forum, formed in 2019, is a Public Private Partnership between ARC and the US Food and Drug Administration (FDA). The goal of the Forum is to leverage expertise and resources from all stakeholders to advance rigorous science to bridge the gaps in drug discovery and development in AL amyloidosis.

The Forum has taken full advantage of the increased capabilities of virtual meetings to expand international representation with the Medicine and Healthcare products Regulatory Agency (MHRA) in the UK joining as well as disease experts from around the globe.

In 2020 the Forum focused on novel endpoint development. Specialized working groups were established consisting of leading physicians, patient representatives, statisticians, regulators, and pharmaceutical company researchers, and statisticians to address the complex and multi systemic nature of AL amyloidosis, and ensure this was reflected in endpoint choice and clinical trial design.

We are pleased to share that the National Institute of Health (NIH) saw the importance of this initiative and provided funding to support Forum meetings.
IMPROVING CARE

HIGHLIGHT

ARC Masterclass

In both AL and ATTR amyloidosis, the treatment and clinical trial landscape has been fast evolving. It has never been more important to ensure that patients are quickly and correctly diagnosed and have access to the appropriate and best treatment. With the complexities associated with treating amyloidosis in its many forms, up-to-date knowledge of treatment options and management are crucial to improving patient outcomes.

ARC Masterclass, launched in January 2020, are led by a nationally/internationally renowned faculty team of amyloidosis experts, and aim to provide education and share established best practices to increase knowledge about amyloidosis, in all its forms, with the healthcare practitioners at these one-day specialized masterclass. These practitioners learn to identify, correctly diagnose, and treat amyloidosis patients in their clinical practice, as well as when and how to refer to specialty centers. The masterclass additionally supports the development of building an amyloidosis program, and the role of a multidisciplinary team to best support patients.
SUPPORTING PATIENTS

Receiving a diagnosis of amyloidosis is frightening, very few people have heard the word amyloidosis before they are diagnosed or know where to turn for help. Patients and families need support, education, and access to specialized care during this difficult time. In 2020, this need for support and resources expanded to include COVID-19 in the ways in which it impacts healthcare and day-to-day life.

ARC provides patients with the comprehensive, unbiased information they need to better understand their disease and the new treatment and care options available in a rapidly changing landscape. ARC has a strong track record of producing scientifically accurate, up-to-date, and relevant information in a patient-friendly format; these include disease-specific guides, webinars, videos, and patient stories to support patients, both those newly diagnosed and those more familiar with their disease. In 2020, ARC’s covid resources became some of the most accessed information to date.

Along with these tangible materials our patient support staff are available daily to speak to patients, and the My Amyloidosis Pathfinder (MAP) tool helps patients navigate finding amyloidosis treatment centers and clinical trials. We believe in empowering patients with the skills to navigate their diagnosis of amyloidosis.

Community Programs

“I picked up the phone, and the Consortium was there and it meant the world to me, just knowing that I wasn’t alone in this fight.”

—Greg, AL amyloidosis
Thanks to the hard work and generosity of our supporters, 2020 was our most impactful year yet. We were able to build unique collaborations and programs to accelerate the research that will change lives of those affected by amyloidosis.
FINANCIALS

ARC 2020 Statement of Activities

Support & Revenue 2020

<table>
<thead>
<tr>
<th>Source of Funds</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$1,783,523</td>
</tr>
<tr>
<td>Other</td>
<td>$215,472</td>
</tr>
<tr>
<td>In-kind contributions</td>
<td>$930</td>
</tr>
<tr>
<td>Interest</td>
<td>$827</td>
</tr>
<tr>
<td><strong>Total Support &amp; Revenue</strong></td>
<td><strong>$2,134,759</strong></td>
</tr>
</tbody>
</table>

Expenses

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Programs Research/Awareness/Education</td>
<td>$1,025,685</td>
</tr>
<tr>
<td>Supporting Services</td>
<td></td>
</tr>
<tr>
<td>Administrative</td>
<td>$95,252</td>
</tr>
<tr>
<td>Fundraising</td>
<td>$122,311</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td><strong>$1,243,248</strong></td>
</tr>
</tbody>
</table>

Change in net assets

<table>
<thead>
<tr>
<th>Asset</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net assets, beginning of year</td>
<td>$1,094,804</td>
</tr>
<tr>
<td><strong>Change in net assets</strong></td>
<td><strong>$891,511</strong></td>
</tr>
<tr>
<td>Net assets, end of year</td>
<td>$1,986,315</td>
</tr>
</tbody>
</table>
2020 BOARDS

Board of Directors

ISABELLE LOUSADA
Founder & CEO
Lincoln, MA

GIAMPAOLO MERLINI, MD
Board Co-Chair
University of Pavia, Italy

RAYMOND COMENZO
Board Co-Chair
Tufts Medical Center, Boston, MA

DENA HEATH
Secretary
Walnut Creek, CA

JASON SHORE
Treasurer
Newton, MA

SARAH CAIRNS-SMITH
Director
Lincoln, MA

Scientific Advisory Board

RAYMOND COMENZO
Tufts Medical Center, Boston, MA

ANGELA DISPENZIERI
Mayo Clinic, Rochester, MN

JEFFERY KELLY
Scripps Research Institute, San Diego, CA

ISABELLE LOUSADA
Amyloidosis Research Consortium

MATHEW MAURER
Columbia University Medical Center, NY

GIAMPAOLO MERLINI
University of Pavia, Italy

VAISHALI SANCHORAWALA
BU Amyloidosis Center, Boston Medical Center, Boston, MA

Nurses Advisory Board

LISA MENDELSOHN
Boston University Amyloidosis Center, Boston, MA

JOHANA FAJARDO
MedStar Washington Hospital, Washington, DC

JANELL GRAZZINI FRANTZ
Mayo Clinic, Rochester, MN

KATHARINA GANAPATHI
UCSF, San Francisco, CA

Patient Advisory Board

DENA HEATH
Walnut Creek, CA

ERIC ECKERSTROM
Fiddletown, CA

NANCY VEREL
Aurora, OH

DAWN GIMBEL-MYERS
Castro Valley, CA

DAVID ANTONAITIS
Endicott, NY

The ARC board and steering committees are comprised of a diverse group of exceptional individuals dedicated to the ARC mission. Together with the ARC staff, they identify areas of opportunity to inform our programs.
Philanthropy fuels every aspect of ARC's mission. We thank every supporter, donor, corporate partner, and foundation for their commitment to helping us accelerate research and move closer to a cure.

WITH GRATITUDE

We thank every supporter, donor, corporate partner, and foundation for their commitment to helping us accelerate research and move closer to a cure.
THANK YOU TO OUR SUPPORTERS

We are working in partnership with today’s leading companies and research institutions to address the unmet need for all types of amyloidosis.
DONOR RECOGNITION

Britt Acklin
Deborah Adams
Nancy & Gary Alan
Allison Alexander
Cyndi Allen
Rose Allen
Jaclyn Alterwein
Christine Alviso
Jennie Alviso
Chris Alviso
Laura Amicucci
Ruth Amir
Richard Andaya
Lena Andaya
Sue Anderson
Dave Anderson
Marilyn Andrew
Karen Antonaitis
Bunny Antonellis
Kathy Aquila
Sharon Armbruster
Lori Ashiotes
Douglas Askew
Margo Assfalag
Carole Auger
Annette Austin
Stefanie Austin
Katherine Austin-Evelyn
Terry Axler
Aras Aziz
Courteney Backstrom
Deann Baker
Raymond Baker
Deb Balika
John Ball
Brooke Bango
Harold Banks
Judith Banks
Theresa Baranowski
Kennedy
Sam Barrett
Burt Bassler
David Bates
Raymond Belin
Sarah Bell
Jenny Bennett
Joy Beranbaum
Jeff Berman
Bob Berry
William Berry
Barbara Bershad
Ann Bettinger Dirobbio
Traci Bigler
Marlene Birch
Bassam Bisso
Michael Bittner
Amanda Black
Joel Blank
Dan Blyweiss
Alex Boala
Deborah Boedicker
Barbara Boehler
Ryan Bogos
Helen Bolen
Pierre Boulos
Susan Bovan
Sarah Bowers
Kurt Brähwiler
Daniel Bradbury
Dan Bramhall
Sandra Bratter
James Bridgeman
Tresa Bridges
Roy Brooks
Keith Brown
Dean Bruskof
Bethany Buckosh
Kelly Buckshire
Daniel Budney
Kim Budney
Paul Burleigh
Julia Burlette
Trevor Burnett
Pamela Busch
Richard Bustamante Quon
Jane Byron
Debra Cain
Sarah Cairns-Smith
Stacey Campbell
Katie Campbell
Colin Campbell
Pete Cannon
Barry Carlin
John Carlisle
Lazell Carr
Sandra Carter
Linda Castleton
Susan Caul
Jan Cawvey
Joan Centofanti
Ramona Chance
Mike Chavez
Caryn Cherpak
Kelsey Cherry-Kelliher
Marie Childs
Carol & Bobby Cicalese
Leigh Anne Clark
Martha Clyburn Lang
Amy Clyde
Judith Coates
Angeleah Coates
Debra Cocchiaro
Allison Cochran
Raymond Comenzo
Michelle Connor
James Cook
Elizabeth Cotton Specht
Linda Courtiss
Henry Harrison
Elizabeth Harrison
Jeanne Harrison
Lauren Harvey
Elaine Haspel
Diana Hawes
Edwina Hawkins
Cecelia Healy
Dena Heath
Jay Hebert
Mary Helen
Linda Hellard
Carol Hendershot
Pat Heying
Darcy Hickey
Kelsy Hiltz
Chris Hm
Ingrid Hollinger
Bob Holt
Judith Horowitz
Friend Household
Staab Household
Phillip Howe
Barbara Howey
Kristen Hsu
Michael Hubley
Dan Hudson
Mohammed Hussain
Prudence Ingram
Debra Jackson
Brad Jacobs
Karen Jacobs
Helene Jaffe
Janice James
Jeanie Jamieson
Emma Jane
David Jenkins
Robin Johnson
Michelle Johnson
Kathy Jones
Sarah Josephine
Jennifer Julian
Mark Jurilla
Sheldon N. Kaftan
David Kanter
Jeff Karoffa
April Karpan-Vadnais
Tracy Kasemeier
Gia Katt
Kevin Keenaghan
Jeffery Kelly
Denis Keohane
Bonnie Kidder
Kiltwalk
Malcolm Kirk
Marilyn Klein
Sharon Kline
Nicole Klionsky
Thomas Kneeshaw
Alexa Knight
Cindi Knoblauch
Kathleen Knopp
John Kolbisen
Kathy Koontz
Loukea Kovannis-Wilson
Julie Koziak
Robert Kropfli
Ron Kulju
John Kulju
Marian Kulju
Nisith Kumar
Kenneth Kuzma
Mary Kyle
Angie Laboyteaux
Anne Lacy
Brett Lacy
Adrienne Lacy
Joshua Landree
Kathy Lane
Kristina Lanza
Anne Larsen
Lisa Lassiter
Julianne Latimer
Virginia Laue
Mike Lawton
Nolen Layman
Marcy Lazar
LC Cape Cod
Carol Lee
Joseph Leffel
Barb Leitch
Corrine Lemberg
Karen Lewis
Gage Libby
Liberty Road Baptist Church
Jonathan Lieber
Giselle Limentanti
Nancy Limprecht
Christina Lindsey
Bob Lobenberg
Lana Long
Maria Lopez
Isabelle Lousada
Sandra Lousada
Desiree Love-Holliday
Eric Low
Melanie Lucas
Debra Luckey
Marcus Lyons
Apryl Lytle
Karen Maciolek
Nancy Maddox
Kevin Maeda
Josh Magier
Shelley Magnusen
Elly Magyar
Carly Malezi
Alex Mallon
Phil Mallon
Barry Mansel
Angie Mar
Terry Marshall
Ramiro Martinez
Maureen Massoletti
Scott Mathews
Tina Matienzo Stiyer
Helen Mayer
Nancy Maynard
Paul Mazzilli
Bonnie McArthur
Rosemarie Mccraig
Richard Mccarthy
Kathryn Mccleary
Teresa Mcconkey Linehan
Diane & Dave Mcdonald
Frank Mcdonald
Angela Mckenna
Teresa Sierak
Deena Silverman
Wendy Silver
Dani Silver
Brad Silverberg
Becca Silverman
Ann Silverman Osborne
Alvin Silverstein
Michelle Silverstein
Reyna Simon
Dorothy Sintas-Abeyta
Farrah Sison
Clara Smallwood
Brie Smarslok
Kathy Smidowski
Alice Smith
Sharon Smith
Dianne Smith
Wayne Smith
Sean Smith
Kimberly Smith Wright
Kathy Smith-Haury
Melissa Sodowick
Alice Charin Sodowick
Maggie Soeder
Peggy Solka
Elizabeth Sollish
Karen Sommer
Glenn Sonoda
Jane Speedy
Laura Stechsulte
Maxwell Stepanuk
Robert Stillman
Bj Stiyer
Rhonda Stiyer
Jennifer Stiyer
Debbie Stocks
Annette Stone
Denise Stone
Susan Stott
Jennifer Strantz
Marcelle Strauss
Leonard Strickland
Stephen Strum
Jon Sufana
Erin Sullivan
Joyce Surdyk
Carol Svetcov
Gary Talewsky
Angelina Tavares
Deborah Tavernia Foote
Eleanor Taylor
Kathleen Taylor
Susan Taylor
James Taylor
Greg Taylor
Ernestine Tegong-Spreemann
Karola Terlaje
Joseph Tersak
David Tetrault
Nell Theodora Chant
Jennifer Thomas
Harriet Thompson
Toni Thompson
Janet Topel
Nathan Toveg
Diane Towles
Gaynell Toy
Víctor Trejo
Stephanie Tsai
Sarah Tuel
Sarah Turnley
Peter Uden
Gail Upton
Susan Utegg
Gregory Vaisleib
Suneet Varma
Nancy Verel
Martin Verel
Kalil Vicious
Rant Vicks
Theresa Vilona Marietti
Pat Wiola
Elizabeth Wagner
Elinda Waldman
Leslie Walker
Judith Wall
Tyler Walsh
Emory Walton
Sharla Walton
Linda Wandres
Kristin Warbasse
Alison Waring
Deborah Warren
Mark Watts
Dorothy Weber
Dan Weinberger
Jeffrey Weiss
Frans Weits
Meadow Welch
Susan Utegg
Nancy Verel
Martin Verel
Kalil Vicious
Rant Vicks
Theresa Vilona Marietti
Pat Wiola
Elizabeth Wagner
Elinda Waldman
Leslie Walker
Judith Wall
Tyler Walsh
Emory Walton
Sharla Walton
Linda Wandres
Kristin Warbasse
Alison Waring
Deborah Warren
Mark Watts
Dorothy Weber
Dan Weinberger
Jeffrey Weiss
Frans Weits
Meadow Welch
Michelle Wells
Mindy Wenger
Katrina Wenger Dyce
Brendan Weyhe
Kristin Wharton
Nathan Wheeler
Thomas Whetsel
John White
Margie Whitson
Ryan Willard
Timothy Willard
Mary Willard
Marilyn & Jon Williams
Diane Williams
Birdie Wilson
Dana Wilson
Keith Wilson
Valerie Winn
Bill Wisch
Paul Wittenberger
Debra Wojtowicz
Cheryl Woodhouse
Ben Wright
Meral Yüksel
Angi Yi
Crystal Young
Amelia Yvonne
Darian Zalewskycostanzo
Ana Zappala
Tonya K Zehner
Laurie Zucarelli Tokarz
Accelerating the development of and access to new and innovative treatments for amyloidosis.